Nondispersive hole transport in a spin-coated dendrimer film measured by the charge-generation-layer time-of-flight method

Published versio

Tuning of emission color for blue dendrimer blend light-emitting diodes

Published versio

Thermal Infrared Radiometric Calibration of the Entire Landsat 4, 5, and 7 Archive (1982-2010)

Landsat's continuing record of the thermal state of the earth's surface represents the only long term (1982 to the present) global record with spatial scales appropriate for human scale studies (i.e., tens of meters). Temperature drives many of the physical and biological processes that impact the global and local environment. As our knowledge of, and interest in, the role of temperature on these processes have grown, the value of Landsat data to monitor trends and process has also grown. The value of the Landsat thermal data archive will continue to grow as we develop more effective ways to study the long term processes and trends affecting the planet. However, in order to take proper advantage of the thermal data, we need to be able to convert the data to surface temperatures. A critical step in this process is to have the entire archive completely and consistently calibrated into absolute radiance so that it can be atmospherically compensated to surface leaving radiance and then to surface radiometric temperature. This paper addresses the methods and procedures that have been used to perform the radiometric calibration of the earliest sizable thermal data set in the archive (Landsat 4 data). The completion of this effort along with the updated calibration of the earlier (1985 1999) Landsat 5 data, also reported here, concludes a comprehensive calibration of the Landsat thermal archive of data from 1982 to the presen

Conjugated dendrimers: A modular approach to materials for full colour displays

Conjugated dendrimers provide an excellent molecular architecture for tuning material properties for organic light emitting diodes. Here we demonstrate a modular approach allowing highly efficient fluorescent and phosphorescent emissive chromophores to be used to make red, green and blue solution-processed light emitting diodes. The choice of a common dendritic architecture ensures good solubility and film forming properties irrespective of the choice of core unit. In addition, this architecture allows blending of dendrimers with different cores without phase separation. We show that blending provides a simple but powerful way of tuning the colour of dendrimer LEDs from deep blue to blue-green, and from green to red with little impact on the device properties

Charge transport in highly efficient iridium cored electrophosphorescent dendrimers

Electrophosphorescent dendrimers are promising materials for highly efficient light-emitting diodes. They consist of a phosphorescent core onto which dendritic groups are attached. Here, we present an investigation into the optical and electronic properties of highly efficient phosphorescent dendrimers. The effect of dendrimer structure on charge transport and optical properties is studied using temperature-dependent charge-generation-layer time-of-flight measurements and current voltage (I-V) analysis. A model is used to explain trends seen in the I-V characteristics. We demonstrate that fine tuning the mobility by chemical structure is possible in these dendrimers and show that this can lead to highly efficient bilayer dendrimer light-emitting diodes with neat emissive layers. Power efficiencies of 20 lm/W were measured for devices containing a second-generation (G2) Ir(ppy)(3) dendrimer with a 1,3,5-tris(2-N-phenylbenzimidazolyl)benzene electron transport layer. (C) 2004 American Institute of Physics

Highly efficient single-layer dendrimer light-emitting diodes with balanced charge transport

Published versio

Neutron reflection study on soluble and insoluble poly[2-(2 '-ethylhexyloxy)-5-methoxy-1,4-phenylenevinylene) films

Neutron reflection (NR) has been utilized to study the physical structure of the light-emitting polymer poly[2-(2'-ethylhexyloxy)-5-methoxy-1,4-phenylenevinylene) (MEHPPV). Films of soluble MEHPPV (S-MEHPPV) and insoluble MEHPPV (I-MEHPPV) prepared via a chloro precursor polymer were investigated. For S-MEHPPV spin-coated films were found to contain two layers, one of low-density and thickness of approximate to1360 Angstrom with the second layer being thinner, approximate to240 Angstrom, but denser. The thicker layer only covered about 30% of the substrate surface. In contrast, I-MEHPPV formed uniform films across the substrate. We found that during the thermal conversion of the chloro precursor polymer the film thickness was maintained and it was only on cooling that the films contracted. Importantly, the thermal expansion and contraction of I-MEHPPV was reversible. NR showed that thermal annealing of I-MEHPPV had little affect on the films physical structure while for S-MEHPPV only the thinner layer was changed and became more dense. Photoluminescence spectra of S-MEHPPV before and after annealing showed that the densification observed in the neutron reflection measurements was mirrored in the emission properties of the polymer film. (C) 2002 American Institute of Physics

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

BACKGROUND: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. METHODS: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. RESULTS: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. CONCLUSIONS: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. FUNDING: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. CLINICAL TRIAL NUMBER: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease

The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted as the document was compiled through December 2008. Repeated literature searches were performed by the guideline development staff and writing committee members as new issues were considered. New clinical trials published in peer-reviewed journals and articles through December 2011 were also reviewed and incorporated when relevant. Furthermore, because of the extended development time period for this guideline, peer review comments indicated that the sections focused on imaging technologies required additional updating, which occurred during 2011. Therefore, the evidence review for the imaging sections includes published literature through December 2011